Christopher T Ritchlin
Overview
Explore the profile of Christopher T Ritchlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
200
Citations
5687
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norton H, Sliwinska-Stanczyk P, Hala T, El-Zorkany B, Stockert L, Mundayat R, et al.
Rheumatol Ther
. 2024 Dec;
12(1):67-84.
PMID: 39636343
Introduction: We assessed tofacitinib efficacy and safety in ankylosing spondylitis (AS) by body mass index (BMI) category. Methods: Data were pooled from phase 2/3 trials; analyses included patients with active...
2.
Deane K, Donlin L, Ritchlin C, Kuhn K
J Rheumatol
. 2024 Oct;
51(12):1229-1234.
PMID: 39448247
Is axial spondyloarthritis (axSpA) one disease or does it comprise multiple types? If the latter, how do we define those types-through clinical or imaging features, HLA-B27 status, or by other...
3.
Gondo G, Noe M, Bell S, Ritchlin C
J Psoriasis Psoriatic Arthritis
. 2024 Sep;
7(1):17-23.
PMID: 39296733
Development and dissemination of novel COVID-19 vaccines represent an opportunity to end the COVID-19 pandemic by vaccinating an estimated 80% of the population. This study examines perceptions, and demographic and...
4.
Mease P, Merola J, Tanaka Y, Gossec L, McInnes I, Ritchlin C, et al.
Rheumatol Ther
. 2024 Aug;
11(5):1363-1382.
PMID: 39215949
Introduction: Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and...
5.
Ritchlin C, Rangel-Moreno J, Martino D, Isett B, Paine A, Bhattacharya S, et al.
JCI Insight
. 2024 Aug;
9(15).
PMID: 39114979
Psoriatic arthritis (PsA) is a complex inflammatory disease that challenges diagnosis and complicates the rational selection of effective therapies. Although T cells are considered active effectors in psoriasis and PsA,...
6.
Kenney H, Chen K, Schnur L, Fox J, Wood R, Xing L, et al.
PLoS One
. 2024 Jul;
19(7):e0305623.
PMID: 38968295
Background: Development of reliable disease activity biomarkers is critical for diagnostics, prognostics, and novel drug development. Although computed tomography (CT) is the gold-standard for quantification of bone erosions, there are...
7.
Ritchlin C, Mease P, Boehncke W, Tesser J, Chakravarty S, Rampakakis E, et al.
Clin Rheumatol
. 2024 Jun;
43(8):2551-2563.
PMID: 38844682
Objectives: Evaluate patterns of stringent disease control with 2 years of guselkumab across key disease-identified domains and patient-reported outcomes (PROs) in subgroups of patients with psoriatic arthritis (PsA) defined by...
8.
Ogdie A, Merola J, Mease P, Ritchlin C, Scher J, Lafferty K, et al.
BMC Rheumatol
. 2024 May;
8(1):20.
PMID: 38773563
Background: Tumor necrosis factor inhibitors (TNFi) are frequently chosen as the first biologic for patients with psoriatic arthritis (PsA). Given that many patients with PsA are TNFi inadequate responders (TNF-IR;...
9.
Krueger J, Eyerich K, Kuchroo V, Ritchlin C, Abreu M, Elloso M, et al.
Front Immunol
. 2024 Apr;
15:1331217.
PMID: 38686385
Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We...
10.
Rahman P, McInnes I, Deodhar A, Schett G, Mease P, Shawi M, et al.
Clin Rheumatol
. 2024 Mar;
43(5):1591-1604.
PMID: 38472528
Objectives: To evaluate the association between enthesitis resolution (ER) and dactylitis resolution (DR) and meaningful improvements in patient-reported outcomes (PROs) among biologic-naïve patients with PsA receiving guselkumab in the DISCOVER-2...